Newsroom
June 16, 2021
Bioventus to Release Second Quarter of Fiscal Year 2021 Financial Results on August 10, 2021
DURHAM, NC – June 16, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today…
May 25, 2021
Bioventus Study Shows Novel Placental Tissue Biologic Candidate Inhibited Inflammatory and Catabolic Responses In Vitro
Demonstrated Significant Reduction of Pain and Cartilage Degeneration in Rat Osteoarthritis Model DURHAM, NC – May 25, 2021 – Bioventus Inc. (Nasdaq:…
May 17, 2021
Bioventus Senior Management to Present at Upcoming Investor Conferences
DURHAM, NC – May 17, 2021 – Senior management of Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for…
May 12, 2021
Bioventus Inc. Reports First Quarter Results; Updates Full Year 2021 Financial Guidance
DURHAM, NC – May 12, 2021 – Bioventus Inc. (Nasdaq: BVS) ("Bioventus" or "the Company"), a global leader in innovations for active healing, today…
April 27, 2021
Bioventus Announces First Commercial Shipment of the Bioness® Integrated Therapy System (BITS) Balance System
Fourteen Facilities Across the US Receive Multidisciplinary Therapy Solution VALENCIA, CA – April 27, 2021 – Bioventus Inc. (Nasdaq: BVS)…
April 12, 2021
Bioventus to Release First Quarter of Fiscal Year 2021 Financial Results on May 12, 2021
DURHAM, NC - April 12, 2021 - Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today…
March 30, 2021
Bioventus Acquires Bioness, Inc.
DURHAM, NC – March 30, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, has…
March 25, 2021
Bioventus Inc. Reports Fourth Quarter and Full Year 2020 Financial Results; Introduces Full Year 2021 Financial Guidance
DURHAM, NC – March 25, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today…
March 11, 2021
Bioventus Reports First Patients Enrolled in Phase 1 Clinical Trial of MOTYS(TM) (PTP-001) for the Treatment of Knee OA
DURHAM, NC – March 11, 2021 – Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a leader in solutions for innovative healing, reported…
